drugset
Drugs / MEDI0680
last change Mar 2020 re-read 8 days ago

MEDI0680

also known as AMP-514

Monoclonal antibody

Developed for
aggressive B-cell non-Hodgkin lymphoma · cancer · clear cell renal carcinoma · high grade malignant neoplasm
Investigated by
MedImmune LLC

Trials 3

today NCT02271945 · Ph 1/2 NCT02118337 · Ph 1/2 NCT02013804 · Ph 1
20142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 11 trial
Phase 1 NCT02013804 Dec 2013 → May 2017 cancer MedImmune LLC Completed No outcome recorded
Phase 1/22 trials · 1 missed
Phase 1/2 NCT02271945 Dec 2014 → May 2016 aggressive B-cell non-Hodgkin lymphoma MedImmune LLC Completed No outcome recorded
Phase 1/2 NCT02118337 May 2014 → Mar 2020 clear cell renal carcinoma, high grade malignant neoplasm MedImmune LLC Completed Missed primary

Evidence & citations 5 cited values

Every value below carries the sentence it was read from. 4 sources stand behind the page.

FieldValueCited text
Known as MEDI0680 ClinicalTrials.gov intervention name — accepted as the source's own label NCT02118337 ↗
2

NCT02271945 ↗

NCT02013804 ↗
Known as AMP-514 “MEDI0680 (AMP-514)” NCT02013804 ↗
Action Inhibit “anti-programmed cell death-1 antibody MEDI0680” PMID 31439037 ↗ Aug 2019
Modality Monoclonal antibody “Anti-PD-1 monoclonal antibody MEDI0680” PMID 31439037 ↗ Aug 2019
Route Intravenous “MEDI0680 was administered intravenously once every 2 weeks (Q2W) or once every 3 weeks” PMID 31439037 ↗ Aug 2019